Buprenorphine physician supply: Relationship with state-level prescription opioid mortality
Buprenorphine physician supply: Relationship with state-level prescription opioid mortality
复制标题
DOI：
10.1016/j.drugalcdep.2016.08.642
复制
发表时间：
2017-04-01
影响因子：
4.2
通讯作者：
Walsh, Sharon L.
中科院分区：
文献类型：
--
作者：
Knudsen, Hannah K.;Havens, Jennifer R.;Walsh, Sharon L.
背景：丁丙诺啡是治疗阿片类药物使用障碍的有效方法，但目前丁丙诺啡医生的供应不足以解决国家的处方阿片类药物危机。由于阿片类药物过量使用率上升而产生的需求感是医生采用丁丙诺啡的可能原因之一。本研究调查了美国各州丁丙诺啡医生增长率与处方阿片类药物过量死亡率之间的关联。方法：测量了 2013 年 6 月至 2016 年 1 月期间丁丙诺啡医生供应总量和批准治疗 100 名患者（每 100,000 人）的医生数量。各州被分为两组：2013 年处方阿片类药物过量死亡率等于或高于中位数的州（每 100,000 人中有 5.5 人死亡）以及死亡率低于中位数的人。使用混合效应回归来估计州级增长曲线，以比较高剂量过量状态和低剂量过量状态之间的增长率。结果：总供应量和 100 名患者丁丙诺啡医生的供应量显着增长（总供应量从每 100,000 人 7.7 人增加到 9.9 人，p
Background: Buprenorphine is an effective treatment for opioid use disorder but the supply of buprenorphine physicians is currently inadequate to address the nation's prescription opioid crisis. Perception of need due to rising opioid overdose rates is one possible reason for physicians to adopt buprenorphine. This study examined associations between rates of growth in buprenorphine physicians and prescription opioid overdose mortality rates in US states.Methods: The total buprenorphine physician supply and number of physicians approved to treat 100 patients (per 100,000 population) were measured from June 2013 to January 2016. States were divided into two groups: those with rates of prescription opioid overdose mortality in 2013 at or above the median (>5.5 deaths per 100,000 population) and those with rates below the median. State-level growth curves were estimated using mixed-effects regression to compare rates of growth between high and low overdose states.Results: The total supply and the supply of 100-patient buprenorphine physicians grew significantly (total supply from 7.7 to 9.9 per 100,000 population, p